Alpha Cognition is a biopharmaceutical company dedicated to developing innovative therapies for patients suffering from neurodegenerative diseases. Our mission is to enhance the quality of life for patients and caregivers by delivering safe, effective, and accessible treatments that address significant unmet needs in neurology.
Our portfolio includes ZUNVEYL®️(Benzgalantamine), an FDA-approved treatment for mild to moderate Alzheimer’s disease, which is also being investigated for cognitive impairment associated with mild traumatic brain injury (mTBI). With over 30 years of collective drug discovery and commercialization experience, our leadership team applies a science-first, patient-focused approach—combining cutting-edge research with a deep understanding of real-world care environments.
We are proud to be one of the few companies actively prioritizing solutions for long-term care settings, supporting both healthcare providers and the residents they serve. Our strategy blends innovation with compassion, ensuring that new scientific breakthroughs are guided by the people and communities who need them most.
At Alpha Cognition, we believe meaningful progress happens where science meets compassion.
Learn more: alphacognition.com
Follow us: Twitter | LinkedIn